- $82.27m
- $10.16m
- 25
- 51
- 75
- 48
Annual income statement for Instil Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.138 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.58 | 33.8 | 156 | 226 | 159 |
Operating Profit | -6.58 | -33.6 | -156 | -226 | -159 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.52 | -37.6 | -157 | -225 | -156 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.52 | -37.7 | -157 | -223 | -156 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.52 | -37.7 | -157 | -223 | -156 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.52 | -37.7 | -157 | -223 | -156 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.04 | -6 | -29.6 | -32.1 | -12.9 |
Dividends per Share |